GlobeNewswire by notified

PRESS RELEASE: BIGBEN : Capital reduction by cancellation of treasury shares

Share

                                                Press release

      Lesquin, 15 September 2022 - 18:00 hrs

Capital reduction by cancellation of treasury shares

The Board of Directors of Bigben Interactive meeting on 15th September 2022 has, pursuant to authorization from the combined general meeting dated July 22, 2022 under the terms of its 30th resolution, decided to reduce the share capital of the Company by cancelling 173,568 treasury shares purchased between May 28, 2022 and July 20, 2022 and representing approximately 0.93% of the share capital of Bigben Interactive.

All of the 173,568 cancelled shares were purchased on the Euronext market in Paris, in accordance with the share purchase mandate given by the Company to CIC Market Solutions, as part of the share buyback programme implemented by a decision of the Board of Directors on January 6, 2022, acting pursuant to the authorisation from the combined general meeting of shareholders on July 30, 2021 under the terms of its 17th resolution and as announced by the Company on January 6, 2022.

Immediately after the cancellation of these shares, the number of shares comprising the share capital of Bigben Interactive amounts to 37,059,920 divided into 18,529,960 shares to which 21,470,130 gross voting rights are attached.

Upcoming events:

Q2 2022/23 sales: Monday 24 October 2022, Press release after close of the Euronext Paris stock exchange

SALES 2021-22
275.7 M€



HEADCOUNT
Over 1200 employees



INTERNATIONAL
31 subsidiaries and a distribution network
in more than 100 countries
www.bigben-group.com


Bigben Interactive is a European player in video game development and publishing, in design and distribution of smartphone and gaming accessories as well as in audio products. The Group, which is recognized for its capacities in terms of innovation and creativity, intends to become one of Europe’s leaders in each of its markets
Company listed on Euronext Paris, compartment B – Index : CAC Mid & Small – Eligible SRD long
ISIN : FR0000074072 ; Reuters : BIGPA ; Bloomberg : BIGFP
PRESS CONTACTS
CapValue – Gilles Broquelet gbroquelet@capvalue.fr - +33 1 80 81 50 01



Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Epiq Service Cloud Delivers Legal Workflow Gen AI Text Summarization6.5.2024 15:22:30 CEST | Press release

Advanced AI is accessible without the need for specialized AI knowledge NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Epiq, a global technology-enabled leader to the legal industry and corporations, today announced Gen AI Text Summarization within the Epiq Service Cloud. This latest feature, powered by Azure OpenAI Service, is adaptable and scalable to support a wide range of legal processes, including eDiscovery and investigations, deposition summaries, mediations, and trials. “Our Gen AI Text Summarization feature underscores Epiq’s commitment to making advanced technology accessible and practical for every legal professional without specialized AI knowledge,” said Eric Crawley, Senior Vice President, Legal Solutions at Epiq. “This feature brings efficiencies to a diverse set of legal workflows while maintaining high standards of accuracy.” The latest Gen AI advancement simplifies the review of complex documents to aid in early case assessment and enhance data analysis. Legal profession

Schouw & Co. aktietilbagekøbsprogram, uge 18 20246.5.2024 15:11:08 CEST | pressemeddelelse

Den 4. marts 2024 iværksatte Schouw & Co. et aktietilbagekøbsprogram som beskrevet i selskabsmeddelelse nr. 13 af 1. marts 2024. I henhold til programmet vil Schouw & Co. i perioden fra 4. marts 2024 til 31. december 2024 købe egne aktier for et maksimalt beløb på 200 mio. kr. Aktietilbagekøbsprogrammet gennemføres i henhold til Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 om markedsmisbrug (MAR) og Kommissionens delegerede forordning (EU) 2016/1052 af 8. marts 2016 ("Safe Harbour”-reglerne). HandelsdagAntal aktierGennemsnitlig kursBeløb Akkumuleret indtil 26/4 2024 79.600 526,89 41.940.547 mandag 29. april 2024 1.900 529,73 1.006.487 tirsdag 30. april 2024 1.000 539,39 539.390 onsdag 1. maj 2024 1.000 555,04 555.040 torsdag 2. maj 2024 1.000 556,37 556.370 fredag 3. maj 2024 1.200 556,39 667.668 I perioden 29/4 2024 - 3/5 2024 6.100 545,07 3.324.955 Samlet i perioden 4/3 2024 - 3/5 2024 85.700 528,19 45.265.502 Ved periodens udløb ejer Schouw & Co. 2.19

Schouw & Co. share buy-back programme, week 18 20246.5.2024 15:11:08 CEST | Press release

On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Trading dayNo. of sharesAverage priceAmount Accumulated until 26/4/2024 79,600 526.89 41,940,547 Monday, 29 April 2024 1,900 529.73 1,006,487 Tuesday, 30 April 2024 1,000 539.39 539,390 Wednesday, 1 May 2024 1,000 555.04 555,040 Thursday, 2 May 2024 1,000 556.37 556,370 Friday, 3 May 2024 1,200 556.39 667,668 In the period 29/4/2024 - 3/5/2024 6,100 545.07 3,324,955 Accumulated 4/3/2024 - 3/5/2024 85,700 528.19 45,265,502 Following the above transactions Schouw & Co. holds a

AKVA group ASA: Status buyback of own shares6.5.2024 14:57:37 CEST | Press release

As announced on 22 March 2024 AKVA group ASA ("AKVA group" or the "Company") has initiated repurchase of up to 200,000 of the company's own shares to be used in its share programme for employees. From 30 April through 6 May the company bought 10 855 shares at an weighted average price of NOK 65,8477. See the attached documents for detailed information about the transactions made. The company has bought a total of 57 896 shares at an weighted average price of NOK 68,3271 since 22 March. After these transactions, the company owns 288 559 treasury shares. This information is made public by the Company pursuant to the EU Market Abuse Regulation article 5, as supplemented by Commission Delegated Regulation (EU) 2016/1052 and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Dated: 6 May 2024 AKVA group ASA Web: www.akvagroup.com CONTACTS: Knut Nesse Chief Executive OfficerPhone:+47 51 77 85 00Mobile:+47 91 37 62 20E-mail:knesse@akvagrou

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®6.5.2024 14:30:00 CEST | Press release

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.” Ampligen is currently being evaluated as

HiddenA line styled icon from Orion Icon Library.Eye